High FSTL3 expression is associated with high malignancy in colorectal, gastric, thyroid, NSCLC, and renal cell carcinoma, which suggest that FSTL3 may be a promising target in the clinical treatment of malignant tumors. The gene discussed is FSTL3; the disease is non-small cell lung carcinoma.